Las Vegas, NV -- (SBWIRE) -- 01/15/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: ReneSola Ltd. (ADR)(NYSE:SOL), American Axle & Manufact. Holdings, Inc.(NYSE:AXL), XOMA Corp(NASDAQ:XOMA), Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX)
ReneSola Ltd. (ADR)(NYSE:SOL) was a volume gainer of 2.26 million shares and the average volume of the stock remained 4.21 million shares. The stock opened the session at $3.77 and finished at the end of the day at $4.03 and the stock escalated 8.04%.The market capitalization of the stock remained 409.63 million. ReneSola Ltd operates as a brand and technology provider of solar photovoltaic (PV) products. ReneSola Ltd was founded in 2005 and is based in Jiashan, the People?s Republic of China.
For How Long SOL will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, American Axle & Manufact. Holdings, Inc.(NYSE:AXL) exchanged 2.29 million shares and the average volume remained 1.09 million shares. The stock closed the session at $20.30 with the gain of 4.53%. American Axle & Manufacturing Holdings, Inc., together with its subsidiaries, engages in the design, engineering, validation, and manufacture of driveline and drivetrain systems, and related components and chassis modules for automotive industry worldwide.
Will AXL Continue To Move Higher? Find Out Here
XOMA Corp(NASDAQ:XOMA) enhanced 5.45% and its closing price was $8.32. The volume of the stock was 2.18 million shares and the average volume remained 2.91 million shares. The market capitalization of the stock remained 862.17 million. The beta of the stock remained 2.41. XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor.
Why Should Investors Buy XOMA After The Recent Gain? Just Go Here and Find Out
Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) exchanged 2.16 million shares in the previous trading session, and its average trading remained 1.05 million shares. PGNX advanced 4.64% and it closed the trading at $6.77. The market capitalization of the stock remained 411.79 million. Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide.
For How Long PGNX’s Gloss will Attract Investors? Find out via this report
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)